Hospira must have read all the legal docs from the Teva suit. Did they conclude that there was something that Teva missed? If not, why are they willing to file a paragraph IV knowing that they will have to spend a couple of million defending the inevitable patent infringement suit?
Regardless of whether the above has any merit, given the potential downside, will new buyers of CBST stock be willing to step up to the plate? I doubt it.
To assert that CBST is a strong buy here, after the strong advance over the last year, fails my risk/reward analysis. JMO.
your opinion is in agreement with 11,500,000 other short shares....but you have some institutions that do not agree with you. If they saw no upside from here...we would be selling off...but I guess you must have missed last quarters earnings release..you know, the one where they beat and raised expectations for next year.